Home » FDA Warns Indian Generics Maker for Multiple GMP Violations
FDA Warns Indian Generics Maker for Multiple GMP Violations
The FDA has warned Indian active pharmaceutical ingredient (API) and generics maker Zydus Group, a division of Cadila Healthcare, for a number of current good manufacturing practice (cGMP) violations, including incomplete test data.
Generic Line
Generic Line
Upcoming Events
-
25Apr
-
07May
-
14May
-
30May